Drug Trial Radar · NCT02594124
A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies
Last checked: Nov 20, 2026Latest source record: Oct 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
292
Actual
Start
Nov 4, 2015
Primary completion
Aug 21, 2023
Study completion Aug 21, 2023
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- First posted
- Nov 2, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective is to evaluate long-term safety and tolerability of nusinersen (ISIS 396443) administered by intrathecal (IT) injection to participants with Spinal Muscular Atrophy (SMA) who previously participated in investigational studies of nusinersen. The secondary objective is to examine the long-term efficacy of nusinersen administered by IT injection to participants with SMA who previously participated in investigational studies of nusinersen.
Conditions
- Spinal Muscular Atrophy
Interventions
nusinersenDrug
Administered by intrathecal (IT) injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Day 1 up to the end of the study (up to 2848 days)
- Number of Participants With Vital Sign Abnormalities Reported as AEsTime frame: From Day 1 up to the end of the study (up to 2848 days)
- Number of Participants With Weight Abnormalities Reported as AEsTime frame: From Day 1 up to the end of the study (up to 2848 days)
- Number of Participants With Neurological Abnormalities Reported as AEsTime frame: From Day 1 up to the end of the study (up to 2848 days)
- Number of Participants With Laboratory Abnormalities Reported as AEsTime frame: From Day 1 up to the end of the study (up to 2848 days)
- Number of Participants With Coagulation Parameters Reported as AEsTime frame: From Day 1 up to the end of the study (up to 2848 days)
- Number of Participants With Clinically Significant Shifts in12 Lead Electrocardiogram (ECG) ResultsTime frame: From Day 1 up to the end of the study (up to 2848 days)
- Number of Participants Taking Any Concomitant MedicationTime frame: From Day 1 up to the end of the study (up to 2848 days)
Locations
47 sites in 14 countries. Site status is shown where the registry gives one.
David Geffen School of Medicine at UCLA
Los Angeles, California
Stanford University School of Medicine
Palo Alto, California
Children's Hospital Colorado
Aurora, Colorado
Connecticut Children's Medical Center
Hartford, Connecticut
Nemours Children's Clinic
Orlando, Florida
Ann & Robert H. Lurie Children's Hospital of Chicago
New York, Illinois
The Johns Hopkins Hospital
Baltimore, Maryland
Boston Children's Hospital
Boston, Massachusetts
Gillette Children's Specialty Healthcare
Saint Paul, Minnesota
Washington University School of Medicine
St Louis, Missouri
Columbia University Medical Center
New York, New York
Duke University School of Medicine
Durham, North Carolina
Duke University School of Medicine
Miyagi, North Carolina
Oregon Health Sciences University
Durham, Oregon
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Children's Medical Center
Dallas, Texas
University of Utah
Obu, Aichi, Utah
Seattle Children's Hospital
Seattle, Washington
Sydney Children's Hospital Clinical Research Centre
Sydney, New South Wales, Australia
Royal Children's Hospital
Parkville, Victoria, Australia
Universitair Kinderziekenhuis Koningin Fabiola
Brussels, Belgium
BC Children's Hospital / UBC
Vancouver, British Columbia, Canada
Children's Health Research Institute
Brussel, Ontario, Canada
McGill University Health Centre
Montreal, Quebec, Canada
Armand Trousseau Hospital, I-Motion
Paris, Paris 9, France
Universitatsklinikum Essen
Essen, Germany
Universitaetsklinikum Freiburg
Freiburg im Breisgau, Germany
LMU-Campus Innenstadt
Munich, Bavaria, Germany
The University of Hong Kong
Hong Kong, Hong Kong SAR, Hong Kong
Pediatric Neurology Unit, Catholic University
Essen, Italy
Istituto Giannina Gaslini, Centro Traslazionale di Miologia
Genova, Italy
Department of Neuroscience, Università di Messina, AOU Polic
Messina, Italy
Kumamoto University Hospital
Kumamoto, Japan
Miyagi Prefectural Children Hospital
Miyagi, Japan
University of Miyazaki Hospital
Miyazaki, Japan
Aichi Children's Health and Medical Center
Ōbu, Aichi-ken, Japan
Hyogo College of Medicine
Nishinomiya, Hyōgo, Japan
Tokyo Women's Medical University
Shinjuku-ku, Tokyo, Japan
Seoul National University Hospital
Seoul, Korea, South Korea
Hospital Sant Joan de Deu
Barcelona, Spain
Showing 40 of 47 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.